日本の自己免疫疾患診断の市場規模は、2024年に3億6,549万ドルと推定され、2025年から2033年にかけて6.6%のCAGRで成長し、2033年までに6億4,045万ドルに達すると予測されます。人口の29%以上が65歳以上を占める世界で最も高齢化が進む日本は、関節リウマチや自己免疫性膵炎などの有病率の増加に直面しています。このため、ANA検査、自己抗体パネル、高度な分子アッセイの需要が高まっています。成長要因には、マルチプレックスイムノアッセイ、AI、バイオマーカー発見の革新と、強力な学術界と産業界の協力などがあります。Sysmex、MB、Autobio Diagnostics,などのパートナーシップにより、精度、拡張性、疾患の早期発見が強化されます。
目次
Table of Contents
Chapter 1. Japan Autoimmune Disease Diagnostics Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type Segment
1.1.1.2. Technology Segment
1.1.1.3. End Use Segment
1.2. Estimates and Forecast Timeline
1.3. Objectives
1.3.1. Objective - 1
1.3.2. Objective - 2
1.3.3. Objective - 3
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information or Data Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. List of Abbreviations
Chapter 2. Japan Autoimmune Disease Diagnostics Market: Executive Summary
2.1. Market Snapshot
2.2. Type and Product Snapshot
2.3. Test Type and End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Japan Autoimmune Disease Diagnostics Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.4.1. Rising demand for early and non-invasive diagnosis
3.4.2. Technological advancements
3.4.3. Academic-industry collaborations
3.5. Market Restraint Analysis
3.5.1. High cost and limited reimbursement coverage
3.6. Market Opportunity Analysis
3.6.1. Expansion of personalized medicine and biomarker-based testing
3.7. Porter’s Five Forces Analysis
3.8. PESTLE Analysis
Chapter 4. Japan Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis
4.1. Japan Autoimmune Disease Diagnostics Market: Type Movement Analysis
4.2. Systemic autoimmune disease diagnostics
4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.2. Rheumatoid arthritis
4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.3. Ankylosing spondylitis diagnostics
4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.4. Systemic lupus erythematosus (SLE)
4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.2.5. Others
4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Localized autoimmune disease diagnostics
4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.2. Multiple sclerosis
4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.3. Type 1 diabetes
4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.4. Hashimoto's Thyroiditis
4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.5. Idiopathic thrombocytopenic purpura
4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3.6. Others
4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Japan Autoimmune Disease Diagnostics Market: Product Estimates & Trend Analysis
5.1. Japan Autoimmune Disease Diagnostics Market: Product Movement Analysis
5.2. Instruments
5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Consumables & Assays
5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Mass spectrometry-based assays
Chapter 6. Japan Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis
6.1. Japan Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
6.2. Antinuclear antibody tests
6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.2.2. Indirect Immunofluorescence (IIF) ANA tests
6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.2.3. ELISA-based ANA tests
6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.2.4. Multiplex/line immunoassay ANA panels
6.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.2.5. Others
6.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Autoantibody tests
6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.2. Rheumatoid Factor (RF) tests
6.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.3. Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
6.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.4. Anti-dsDNA tests
6.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.5. Anti-Smith (Sm) antibody tests
6.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.6. Anti-Ro/SSA & Anti-La/SSB antibody tests
6.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.7. Others
6.3.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. C-reactive Protein (CRP)
6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Complete blood count (CBC)
6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Urinalysis
6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Others
6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Japan Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis
7.1. Japan Autoimmune Disease Diagnostics Market: End Use Movement Analysis
7.2. Hospitals
7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.3. Diagnostic Centers
7.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4. Others
7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. NEW PRODUCT LAUNCH
8.2.2. PARTNERSHIPS
8.2.3. ACQUISITION
8.2.4. COLLABORATION
8.2.5. FUNDING
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. Fujirebio
8.5.2. SEKISUI MEDICAL CO., LTD
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Medical & Biological Laboratories (MBL)
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Bio-Rad Laboratories, Inc.
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Abbott
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. F. Hoffmann-La Roche, Ltd.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Siemens Healthineers AG
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Sysmex Corporation
8.5.8.1. Grifols Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. BioMérieux
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Beckman Coulter ( Danaher)
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List 0f Abbreviation
Table 2 Japan Autoimmune Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 3 Japan Autoimmune Disease Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 4 Japan Autoimmune Disease Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
Table 5 Japan Autoimmune Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Japan autoimmune disease diagnostics market - Key market driver analysis
Fig. 7 Japan autoimmune disease diagnostics market - Key market restraint analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Japan autoimmune disease diagnostics market - Porter’s analysis
Fig. 10 Japan autoimmune disease diagnostics market - PESTEL analysis
Fig. 11 Japan autoimmune disease diagnostics market Type outlook key takeaways
Fig. 12 Japan autoimmune disease diagnostics market : Type movement analysis
Fig. 13 Systemic autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
Fig. 14 Rheumatoid arthritis market estimates, 2021 - 2033 (USD Million)
Fig. 15 Ankylosing spondylitis diagnostics market estimates, 2021 - 2033 (USD Million)
Fig. 16 Localized autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
Fig. 17 Multiple sclerosis market estimates, 2021 - 2033 (USD Million)
Fig. 18 Type 1 diabetes market estimates, 2021 - 2033 (USD Million)
Fig. 19 Hashimoto's Thyroiditis market estimates, 2021 - 2033 (USD Million)
Fig. 20 Idiopathic thrombocytopenic purpura market estimates, 2021 - 2033 (USD Million)
Fig. 21 Others market estimates, 2021 - 2033 (USD Million)
Fig. 22 Japan autoimmune disease diagnostics market product outlook key takeaways
Fig. 23 Japan autoimmune disease diagnostics market : product movement analysis
Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
Fig. 25 Consumables & Assays market estimates, 2021 - 2033 (USD Million)
Fig. 26 Japan autoimmune disease diagnostics market Test type outlook key takeaways
Fig. 27 Japan autoimmune disease diagnostics market : Test type movement analysis
Fig. 28 Antinuclear antibody tests market estimates, 2021 - 2033 (USD Million)
Fig. 29 Indirect Immunofluorescence (IIF) ANA tests market estimates, 2021 - 2033 (USD Million)
Fig. 30 ELISA-based ANA tests market estimates, 2021 - 2033 (USD Million)
Fig. 31 Multiplex/line immunoassay ANA panels market estimates, 2021 - 2033 (USD Million)
Fig. 32 Others market estimates, 2021 - 2033 (USD Million)
Fig. 33 Autoantibody tests market estimates, 2021 - 2033 (USD Million)
Fig. 34 Rheumatoid Factor (RF) tests estimates, 2021 - 2033 (USD Million)
Fig. 35 Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests estimates, 2021 - 2033 (USD Million)
Fig. 36 Anti-dsDNA tests estimates, 2021 - 2033 (USD Million)
Fig. 37 Anti-Smith (Sm) antibody tests estimates, 2021 - 2033 (USD Million)
Fig. 38 Anti-Ro/SSA & Anti-La/SSB antibody tests estimates, 2021 - 2033 (USD Million)
Fig. 39 Others estimates, 2021 - 2033 (USD Million)
Fig. 40 C-reactive Protein (CRP) market estimates, 2021 - 2033 (USD Million)
Fig. 41 Complete blood count (CBC) market estimates, 2021 - 2033 (USD Million)
Fig. 42 Urinalysis market estimates, 2021 - 2033 (USD Million)
Fig. 43 Others market estimates, 2021 - 2033 (USD Million)
Fig. 44 Japan autoimmune disease diagnostics market end use outlook key takeaways
Fig. 45 Japan autoimmune disease diagnostics market : end use movement analysis
Fig. 46 Hospitals market estimates, 2021 - 2033 (USD Million)
Fig. 47 Diagnostic Centers market estimates, 2021 - 2033 (USD Million)
Fig. 48 Others market estimates, 2021 - 2033 (USD Million)
Fig. 49 Strategy framework
